

Special Issue

Fish as Model Organism for the Identification of Marine Bioactive Compounds

Message from the Guest Editor


Dear colleagues, Zebrafish (*Danio rerio*) and medaka (*Oryzias latipes*) are currently used as model organisms for the screening of molecules of interest for biomedical and pharmaceutical applications, and, in particular, for the identification of compounds capable of rescuing fish phenotypes mimicking human diseases. The marine environment, with its large diversity of habitats, hosts a plethora of species with a large diversity of physiological adaptations, which are the source of structurally unique natural products. In recent years, a number of molecules/extracts with specific biomedical applications have been isolated from marine organisms, and these proven to be effective in targeting prevalent and rare diseases or as sources to develop new analgesics, anti-inflammatory or antidiabetic drugs, to name only a few. The present Special Issue aims to bring together articles presenting a comprehensive overview of the use of fish as model organisms to identify marine derived compounds of biomedical interest.

Guest Editor

Prof. Dr. M. Leonor Cancela
Ctr Marine Sci CCMAR, Univ Algarve, 8005-139 Faro, Portugal

Deadline for manuscript submissions

closed (30 June 2022)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/76925

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))